Ofatumumab in Relapsing Multiple Sclerosis: Observational Study
An observational study aimed to evaluate the serum immunoglobulin G (IgG) levels in 115 adult patients with relapsing multiple sclerosis who were treated with ocrelizumab for at least 18 months. The study compared these levels during subsequent treatment with ofatumumab over 24 months. However, no results have been posted, and endpoints are not reported as findings.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
Understanding IgG levels could provide insights into immune responses during MS treatment, potentially influencing future therapies and management strategies for MS.
What this does not prove
No results are available, meaning the effectiveness and outcomes of the treatment cannot be evaluated. The planned enrollment and endpoints do not constitute actual findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 115 · planned enrolment
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Adult patients (≥18 years) with relapsing multiple sclerosis treated with ocrelizumab for at least 18 months
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Trial registrationSwitch to Ofatumumab and Level of Immunoglobulins ↗
Supporting passages (12)
study designStudy type: Observational
sample sizeEnrollment: 115 participants (estimated)
subjectsParticipants: people; ages from 18 Years to 65 Years; sex All
primary endpointPrimary endpoints: Slope of serum immunoglobulin G (IgG) levels during ocrelizumab treatment period (minimum 18 months); Slope of serum immunoglobulin G (IgG) levels during ofatumumab treatment period (24 months)
limitationsNo results are posted.
limitationsPlanned enrolment and endpoints are not findings.
populationAdult patients (≥ 18 years old) who had been treated with ocrelizumab for a relapsing form of Multiple Sclerosis according to the ocrelizumab marketing authorization (MA) treatment regimen for at least 18 months.\n2.
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
interventionInterventions: ofatumumab
follow upFollow-up: 42 months; Baseline; 24 months; 18 months
sample size basisEnrollment: 115 participants (estimated)
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.